Institutional
Atlas Venture Life Science Advisors, LLC
CIK 0001917529
$790.0M
Reported AUM
6
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · Atlas Venture Life Science Advisors, LLC · Q1 2026
AI · grounded in 13F
Atlas Venture Life Science Advisors, LLC closed its position in Day One Biopharmaceuticals, Inc. DAWNGBX, reducing its holdings by $59.77M. The fund also exited its position in Generation Bio, Co., resulting in a $4.7M decrease. Additionally, the fund trimmed its stake in Kymera Therapeutics, Inc. KYMR by 1.76%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | $103.40 | -3.37% | 140.69% | 66.40% | $381.3M | 48.26% | — | HELD |
| 2 | DYN | Dyne Therapeutics, Inc. | $25.18 | -2.14% | 150.55% | 48.73% | $165.5M | 20.95% | — | HELD |
| 3 | SION | Sionna Therapeutics, Inc. | $47.13 | 0.75% | 178.55% | 350.57% | $120.1M | 15.20% | — | HELD |
| 4 | IRON | Disc Medicine, Inc. | $77.00 | -2.79% | 30.57% | -47.83% | $96.8M | 12.25% | — | HELD |
| 5 | QTTB | Q32 Bio, Inc. | $15.68 | 0.77% | 684.00% | -87.88% | $13.4M | 1.70% | — | HELD |
| 6 | KRRO | Korro Bio, Inc. | $10.37 | -0.77% | -25.13% | -97.31% | $12.9M | 1.63% | — | HELD |
Source: SEC EDGAR · accession 0001104659-26-061232. 13F discloses long positions only — shorts, foreign equities, and options are excluded.